Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Invests $2M in Protedyne; Companies to Co-Market HT Nucleic Acid-Purification Tech

NEW YORK, Feb. 1 (GenomeWeb News) - Qiagen and Protedyne will jointly market the use of Protedyne's BioCube system with Qiagen's QIAamp nucleic acid purification products for use in high-throughput research and molecular diagnostics, the companies said today.


In addition, Qiagen will invest approximately $2 million in Protedyne's current Series D financing round, the companies said.


Qiagen has exclusive access to BioCube, Protedyne's high-throughput automation platform. The companies originally agreed to develop the high-throughput nucleic acid sample-preparation platform in June 2004.


The companies said that the first commercial platform will be available in the second quarter of 2005, at which point both parties are expected to expand their collaboration by adding and validating additional applications.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.